Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 470

1.

A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia.

Verstovsek S, Courby S, Griesshammer M, Mesa RA, Brachmann CB, Kawashima J, Maltzman JD, Shao L, Xin Y, Huang D, Bajel A.

Leuk Res. 2017 May 30;60:11-17. doi: 10.1016/j.leukres.2017.05.002. [Epub ahead of print]

2.

Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.

Miller CB, Komrokji RS, Mesa RA, Sun W, Montgomery M, Verstovsek S.

Clin Lymphoma Myeloma Leuk. 2017 May 12. pii: S2152-2650(17)30163-5. doi: 10.1016/j.clml.2017.05.015. [Epub ahead of print]

PMID:
28606598
3.

Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.

Masarova L, Bose P, Daver N, Pemmaraju N, Newberry KJ, Manshouri T, Cortes J, Kantarjian HM, Verstovsek S.

Leuk Res. 2017 Jun 2;59:110-116. doi: 10.1016/j.leukres.2017.06.001. [Epub ahead of print]

PMID:
28601551
4.

Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome.

Jain P, Wang S, Patel KP, Sarwari N, Cortes J, Kantarjian H, Verstovsek S.

Leuk Res. 2017 Jun 1;59:105-109. doi: 10.1016/j.leukres.2017.05.018. [Epub ahead of print]

PMID:
28599188
5.

Morphologic and Molecular Characteristics of De Novo AML With JAK2 V617F Mutation.

Hidalgo-López JE, Kanagal-Shamanna R, Medeiros LJ, Estrov Z, Yin CC, Verstovsek S, Konoplev S, Jorgensen JL, Mohammad MM, Miranda RN, Zhao C, Lee J, Zuo Z, Bueso-Ramos CE.

J Natl Compr Canc Netw. 2017 Jun;15(6):790-796. doi: 10.6004/jnccn.2017.0106.

PMID:
28596259
6.

Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.

Falchi L, Kantarjian HM, Verstovsek S.

Leukemia. 2017 May 22. doi: 10.1038/leu.2017.150. [Epub ahead of print] Review.

PMID:
28529308
7.

JAK2 inhibitors for myeloproliferative neoplasms: what is next?

Bose P, Verstovsek S.

Blood. 2017 May 12. pii: blood-2017-04-742288. doi: 10.1182/blood-2017-04-742288. [Epub ahead of print]

PMID:
28500170
8.

Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified from reactive idiopathic hypereosinophilic syndrome.

Wang SA, Hasserjian RP, Tam W, Tsai AG, Geyer JT, George TI, Foucar K, Rogers HJ, Hsi ED, Rea BA, Bagg A, Bueso-Ramos C C, Arber DA, Verstovsek S, Orazi A.

Haematologica. 2017 May 11. pii: haematol.2017.165340. doi: 10.3324/haematol.2017.165340. [Epub ahead of print]

9.

Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera.

Tang G, Hidalgo Lopez JE, Wang SA, Hu S, Ma J, Pierce S, Zuo W, Carballo-Zarate AA, Yin CC, Tang Z, Li S, Medeiros LJ, Verstovsek S, Bueso-Ramos CE.

Haematologica. 2017 May 4. pii: haematol.2017.165795. doi: 10.3324/haematol.2017.165795. [Epub ahead of print]

10.

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.

Vannucchi AM, Verstovsek S, Guglielmelli P, Griesshammer M, Burn TC, Naim A, Paranagama D, Marker M, Gadbaw B, Kiladjian JJ.

Ann Hematol. 2017 Jul;96(7):1113-1120. doi: 10.1007/s00277-017-2994-x. Epub 2017 Apr 30.

PMID:
28456851
11.

Investigational Janus kinase inhibitors in development for myelofibrosis.

Bose P, Abou Zahr A, Verstovsek S.

Expert Opin Investig Drugs. 2017 Jun;26(6):723-734. doi: 10.1080/13543784.2017.1323871. Epub 2017 May 8. Review.

PMID:
28441920
12.

A case of lymphocytic variant hypereosinophilic syndrome with sub-diagnostic systemic mastocytosis.

Jain P, Wang SA, Yin CC, Abaza Y, Verstovsek S, Estrov Z.

Blood Res. 2017 Mar;52(1):71-73. doi: 10.5045/br.2017.52.1.71. Epub 2017 Mar 27. No abstract available.

13.

Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.

Boddu PC, Kantarjian HM, Ravandi F, Garcia-Manero G, Verstovsek S, Jabbour EJ, Takahashi K, Bhalla K, Konopleva M, DiNardo CD, Ohanian M, Pemmaraju N, Jain N, Pierce S, Wierda WG, Cortes JE, Kadia TM.

Cancer. 2017 Apr 7. doi: 10.1002/cncr.30704. [Epub ahead of print]

PMID:
28387922
14.

The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review.

Boddu P, Falchi L, Hosing C, Newberry K, Bose P, Verstovsek S.

Leuk Res. 2017 Jul;58:14-22. doi: 10.1016/j.leukres.2017.03.008. Epub 2017 Mar 22. Review.

PMID:
28380402
15.

3q26.2/EVI1 rearrangement is associated with poor prognosis in classical Philadelphia chromosome-negative myeloproliferative neoplasms.

Hu Z, Medeiros LJ, Wang W, Chen Z, Tang G, Hodjat P, Yang S, Fang L, Li Y, Verstovsek S, Hu S.

Mod Pathol. 2017 Mar 24. doi: 10.1038/modpathol.2017.19. [Epub ahead of print]

PMID:
28338652
16.

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.

Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G.

Leukemia. 2017 Mar 24. doi: 10.1038/leu.2017.85. [Epub ahead of print] No abstract available.

PMID:
28338082
17.

Haptoglobin is frequently low in patients with myelofibrosis: Clinical relevance.

Strati P, Masarova L, Bose P, Daver N, Pemmaraju N, Verstovsek S.

Leuk Res. 2017 Mar 8;57:85-88. doi: 10.1016/j.leukres.2017.03.006. [Epub ahead of print]

PMID:
28324773
18.

Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma.

Short NJ, Kantarjian HM, Ko H, Khoury JD, Ravandi F, Thomas DA, Garcia-Manero G, Khouri M, Cortes JE, Wierda WG, Verstovsek S, Estrov Z, Ferrajoli A, Thompson PA, Pierce S, O'Brien SM, Jabbour E.

Am J Hematol. 2017 Jun;92(6):E114-E117. doi: 10.1002/ajh.24720. Epub 2017 Apr 18. No abstract available.

PMID:
28295472
19.

Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial.

Masarova L, Patel KP, Newberry KJ, Cortes J, Borthakur G, Konopleva M, Estrov Z, Kantarjian H, Verstovsek S.

Lancet Haematol. 2017 Apr;4(4):e165-e175. doi: 10.1016/S2352-3026(17)30030-3. Epub 2017 Mar 11.

PMID:
28291640
20.

Quality and cost comparison of powered versus manual bone marrow biopsy devices in patients with myelofibrosis.

Maiti A, Short NJ, Verstovsek S, Powers CA, Fullmer CA, Reyes SR, Bueso-Ramos CE.

Leuk Lymphoma. 2017 Feb 28:1-3. doi: 10.1080/10428194.2017.1295147. [Epub ahead of print] No abstract available.

PMID:
28264600

Supplemental Content

Loading ...
Support Center